Quantification of HER family receptors in breast cancer
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron)
Radosevic-Robin, Nina (Jean Perrin Comprehensive Cancer Center)
Ng, Tony (University College London. UCL Cancer Institute)
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center)
Universitat Autònoma de Barcelona

Date:	2015
Abstract:	he clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Published in:	Breast cancer research, Vol. 17 (april 2015) , ISSN 1465-542X

DOI: 10.1186/s13058-015-0561-8
PMID: 25887735

12 p, 471.1 KB

The record appears in these collections:
Articles > Published articles